

Cumulative Index 1991

Volume 14

March	PERVASIVE DEVELOPMENTAL DISORDERS, pages 1-222
June	ALZHEIMER'S DISEASE, pages 223-487
September	MULTIPLE PERSONALITY DISORDER, pages 489-791
December	ELECTROCONVULSIVE THERAPY, pages 793-1035

Note: Page numbers of article titles are in **boldface** type.

Abreactions, fractionated, MPD treatment and, 672-673
Acetylcholine, in Alzheimer's disease, 422-423
Acetylcholine precursors, for cognitive impairment in Alzheimer's disease, 467
Acetylcholinesterase, in Alzheimer's disease, 290
Acetylcholinesterase inhibitors, for cognitive impairment in Alzheimer's disease, 464-467
Acetyl-L-carnitine, for cognitive impairment in Alzheimer's disease, 470
Activities of daily living scales, in Alzheimer's disease, 318-320
Ad hoc multiple personality disorder, 625
Adolescents. *See also Children.*
dissociative disorders in, 519-529
Affect, autism and, 25-27, 130
Affective symptoms, in MPD, 601-602, 730-731
Age, parental, and Alzheimer's disease risk, 259
seizure threshold and, in ECT, 813-815
Age regression, spontaneous, MPD and, 581-582
Aging, normal, senile dementia of Alzheimer type versus, 398-400
Agitation, in Alzheimer's disease, 342-344
Alter personalities. *See also Alternative identities; Multiple personality disorder (MPD).*
attributes and presence of, 593-594
automatic thoughts of, 663-665
blending of, 673-674
characteristics of, 610-611
like-clusters of, MPD treatment and, 672
mapping of, 670-671
physiological differences in, 491-494
switching between, 598-600
eye roll with, 585-586
Alternative identities. *See also Alter personalities.*
embodied, 769-785
Alzheimer's disease, 223-487
assessment of, 309-322
behavioral problems in, 341-349. *See also Behavioral problems, in Alzheimer's disease.*
causes of death and, 257-258
CERAD and, 225-228
clinical diagnosis of, 223-234
problem of, 251-252
clinical diagnostic criteria of, 223-225
clinical genetic studies of, 267-284
case-control studies, 268
family history studies of cumulative risk, 269-275
future prospects for, 282-284
genetic linkage studies, 276-282
pedigree studies, 276
twin studies, 268-269
cognitive impairment in, treatment of, 461-474
course of, 223-234
definition of, 251
depression in, 327-336. *See also Depression, in Alzheimer's disease.*

Alzheimer's disease (Continued)

- diagnosis of, accuracy of, 253
- differential diagnosis of, 229–230, 237–246
- Down's syndrome and, 259
- epidemiology of, 228, 251–261
- familial aggregation of, 258–259
- family counseling and legal issues in, 385–394
- histologic diagnosis of, problem of, 252–253
- incidence of, 254
- lifetime cumulative risk of, 254–255
- longitudinal course of, 233
- magnitude of, 253–261
- and mortality, 256
- neurochemical and receptor changes in, 290–291
- neuroimaging in, 443–455
- neurotransmitter systems and, 288–300, 409–410
 - neuropeptides and, 421–434
 - noncognitive abnormalities in, 341–349
 - normal aging versus, 398–400
 - parental age and, 259
 - Parkinson's disease and, 259
 - pathology of, 397–414
 - amyloid and diffuse plaques in, 400–406
 - extraneuronal manifestations of, 410–411
 - granulovascular neuronal degeneration in, 409
 - Hirano bodies in, 409
 - historical aspects of, 397–398
 - hypotheses of, 411–414
 - neurofibrillary tangles in, 406–409
 - neurotransmitter systems in, 409–410
 - vascular disease and, 411
 - pharmacologic models of, 287–303
 - prevalence of, 254
 - prognostic factors in, 257
 - risk factors for, 258–261
 - staging of, 315–318
 - and survival, 256
 - thyroid disease and, 259, 261
 - variations in, by persons, place, and time, 255
- Alzheimer's Disease Assessment Scale, 313
 - noncognitive subscale of, 322
- Amino acid neurotransmitters, in Alzheimer's disease, 432–433
- 4-Aminopyridine, for cognitive impairment in Alzheimer's disease, 467
- Amnesia symptoms, in mental status examination for assessment of MPD and dissociative disorders, 572–580
- Amyloid, and diffuse plaques, in Alzheimer's disease, 400–406, 472
- Anesthesia/analgnesia, effect on seizure threshold, in ECT, 815–816
 - voluntary, MPD and, 583–584
- Aneurysm, aortic, ECT and, 877
- Animal models of Alzheimer's disease, 293–295
- Anticonvulsants, and seizure threshold, in ECT, 817–819
- Antidepressants, in MPD, 733–734
 - tricyclic, and cholinergic function, 299
 - and seizure threshold, in ECT, 819
- Antihypertensives, ECT and, 874
- Antipsychiatry movement, impact of, on revival of ECT in United States, 793–800
- Antipsychotics, and cholinergic function, 299–300
- Antisocial personality disorder, comorbidity of MPD and, 559–560
- Anxiety, MPD and, 590–591, 732–736
- Aortic aneurysm, ECT and, 877
- Appearance, MPD and, 570
- Asperger's syndrome, 81–91
 - assessment of, 88
 - associated handicaps with, 86–87
 - diagnostic features of, 82–83
 - differential diagnosis of, 83–86
 - etiology of, 87–88
 - outcome of, 90–91
 - phenotype and, 129
 - treatment of, 88–90
- Assessment scales, for Alzheimer's disease, 309–322
- Attachment, autism and, 27
- Attention, Alzheimer's disease and, scopolamine and, 295, 297
- Atypical development, 55–56
- Atypical multiple personality disorder, 623
- "Atypical ontogeny," 54–55
- order
- Autism, 1–14. *See also Autistic disorder.*
- affect and, 25–27, 130
- Asperger's syndrome versus, 83–85
- clinical description of, 1–2
- developmentally ordering symptoms of, 53–54
- diagnosis of, décalage as organizing construct in, 60–62
- future trends in, 76–77
- interpretation of results of measures in, 75–76
- issues in conceptualization of, 70–73
- methods and measures of behavior in, 69–78
- methods of information collection for, 73–75
- false-negative diagnosis of, DSM scoring procedure and, 62
- fragile X and, 131–133
- genetic influences in, 125–137
- interactive studies of, 27
- language impairment and, 11, 23–25, 102–104
- normal development versus, 8–10

psychiatric treatment of, functional neuroanatomy of, 118–122
 research strategies applied to, 3–5
 social deviance in, 19–30
 theory of, 2–8, 10–13
 theory of mind in, 33–48
 tuberous sclerosis and, 133–135
 understanding of mental states in, 35–36

Autistic disorder. *See also Autism.*
 developmental approach to, 53–67
 developmental measures and, DSM-IV and, 62–65
 diagnosis of, DSM-III-R procedures for, 61–62
Autohypnotic symptoms, in mental status examination for assessment of MPD and dissociative disorders, 580–586

Automatic thoughts, MPD and, 663–665

Autonomic response, monitoring of, in electroconvulsive therapy, 847

Avoidance, MPD and, 592–593

Avoidant personality disorder, comorbidity of MPD and, 560–561

Behavior, form and function of, 56
 longevity, duration, and frequency of, 57–58
 MPD and, 570–571, 573–574

Behavioral assessment, in child dissociative disorder diagnosis, 636–639
 noncognitive, in Alzheimer's disease, 320–322

Behavioral pathology in Alzheimer's Disease scale, 321–322

Behavioral problems, in Alzheimer's disease, 341–349
 agitation, 342–344
 benzodiazepines in management of, 380–381
 neuroleptic drugs in management of, 353–371
 passivity, 345
 prevalence of, 341–342
 psychosis and, 345–346
 sleep disturbance and, 346
 therapeutic approaches to, 347–348, 353–371, 380–381
 wandering, 344–345

in dementia, benzodiazepines and, 375–383
 management of, child dissociative disorders and, 644–646

Behavioral states, 524–525

Behavioral traits, genetic influences on, 125–126

Benzodiazepines, behavioral symptom management with, in demented patients, 375–383
 and cognitive impairment, 301–302
 in MPD, 735–736
 and seizure threshold, in ECT, 817–819
Beta-amyloid, and cognitive impairment in Alzheimer's disease, 471

Beta-blockers, in MPD, 734–735

Beta-endorphins, in Alzheimer's disease, 429, 430

Biologic markers, primary degenerative dementia and, 245

Bipolar disorder, ECT in, prophylactic, 955

Birth complications, and speech and language disorders, 98–99

Birth order, and speech and language disorders, 98

Blackouts, in MPD, 573

Blessed rating instruments, for dementia assessment, 310–311

Blood flow, cerebral, ECT and, 877–878
 regional, Alzheimer's disease and, 453–454

Blood pressure, agents lowering, ECT and, 874

Body. *See also Physiology.*
 embodied alternative identities and, identification of, 773–774

Body schema, development of, 152–153

Borderline personality disorder, comorbidity of MPD and, 556–559
 MPD versus, 544

Brain, ECT effects on, 877–878
 fluid volume in, Alzheimer's disease and, 445–446

Brain peptides. *See Neuropeptides.*

Brain tumor, ECT and, 878–880

Brief Cognitive Rating Scale, 312–313

Caffeine, ECT and, 861–863

Calcium channel blockers, for cognitive impairment in Alzheimer's disease, 471

Cardiac pacemakers, ECT and, 876

Cardiovascular system, ECT effects on, 872–873
 risk management, 873–877

Caregiver. *See also Family entries.*
 Alzheimer's disease and, burden of, 386–387
 negative impact of, 386–387

Case management, psychotherapy and, for MPD, 649–659

Central nervous system, ECT and, risk management, 878–881

Central nervous system peptides. *See Neuropeptides.*

CERAD (Consortium to Establish a Registry for Alzheimer's Disease), 225–228

Cerebral blood flow, ECT and, 877–878

Cerebral permeability, ECT and, 878

Cerebral trauma, ECT and, 880–881

Cerebral vascular malformation, ECT and, 880

Children, autistic. *See Autism.*

- with autistic features, in Asperger's syndrome, 81-82. *See also Asperger's syndrome.*
- disabled, family and, 199-213
 - parental reactions to, 185-192
 - dissociative disorders in, 519-529
 - developmental substrates of, 520-526
 - diagnosis of, 526-528, 632-640
 - diagnostic and conceptual issues in, 520
 - differential diagnosis of, 639-640
 - future study of, 529
 - treatment of, 528, 631-647
 - normal. *See also Development, normal.*
 - development of theory of mind in, 36-37
 - psychopathology in, developmental and medical models for, 54-58
 - schizotypal personality disorder in, Asperger's syndrome versus, 86
 - trauma in. *See Trauma, childhood.*
- Cholecystokinin octapeptide, in Alzheimer's disease, 431
- Choline acetyltransferase, in Alzheimer's disease, 290
- Cholinergic agonists, for cognitive impairment in Alzheimer's disease, 462-464
- Cholinergic system, and Alzheimer's disease, 289-292
 - clinical, neurochemical, and neuro-pathologic correlates of, 291-292
 - neurochemical and receptor changes in, 290-291
 - pharmacology and, 295-300
 - scopolamine and, 295-299, 300
 - anatomy of, 289, 290
 - neurochemistry of, 289, 291
- Cholinomimetic drugs, for cognitive impairment in Alzheimer's disease, 462-467
- Chromosomes, genetic markers on, Alzheimer's disease and, 279-281
- Clinical Dementia Rating scale, 226, 317
- Clinician, MPD patient's impact on, 571
- Clonidine, in MPD, 734-735
- Cluster A personality disorders, MPD and, 550-553
- Cluster B personality disorders, MPD and, 553-560
- Cluster C personality disorders, MPD and, 560-564
- Coconscious multiple personality disorder, 622
- Cognition-enhancing drugs, in Alzheimer's disease, 469-470
- Cognitive dissonance, establishment of, in MPD, 665-670
- Cognitive function, autism and, 11
- Cognitive impairment, in Alzheimer's disease, treatment of, 461-474
- drugs and, 300-302
- stimulus intensity and, in ECT, 807-808
- Cognitive model, in MPD treatment, 662-674
- Cognitive restructuring, with MPD patients, 663-665
- Cognitive-developmental systems theory in pervasive developmental disorders, 141-161
 - correction of developmental dysfunctions and, 149-160
 - integration of center and home and, 160-161
 - reality systems and, 147-149
 - sign stage of development and, 142-147
- Collaborative evaluation, legal evidence and, MPD and, 751
- Communication. *See also Language disorders.*
 - development of, developmental dysfunctions and, 156-160
 - forensic issues of, MPD and, 752-753
 - with outpatient psychotherapist, hospitalized MPD patient and, 710-711
- Community referral, Alzheimer's disease and, family and, 389
- Companionship, imaginary, 523-524
- ostensible, 623
- Compensatory action phase of sign stage of development, 145-147
- Competency, Alzheimer's disease and, 391-392
 - to stand trial, MPD and, 742-746
 - substitute consent and, for ECT, 1010-1012
- Comprehensive dementia assessments, 310-313, 317
- Compulsive personality disorder, comorbidity of MPD and, 561-562
- Computerized tomography, in Alzheimer's disease, 444-446
- Consent, informed. *See Informed consent.*
 - substitute, for ECT, 1010-1012
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 225-228
- Contact, synchrony of, autism and, 27
- Continuity of care, MPD and, 649-659
- Cooperation with outpatient psychotherapist, hospitalized MPD patient and, 710-711
- Coping, developmental dysfunctions and, 153-155
 - general style of, MPD and, 537-538
- Cornell Scale for Depression in Dementia, 321
- Corticotropin releasing factor, in Alzheimer's disease, 427-429

Covert multiple personality disorder, 623–625

Craniotomy, ECT and, 880–881

Crisis management, in MPD, 657–659

Crisis prevention, in MPD, 661–674

Death instinct, identity and development and, in MPD, 683–686

Décalage, as organizing construct in autism diagnosis, 60–62

Dementia, assessment of, 310–313

- behavioral symptoms of. *See also Behavioral problems, in Alzheimer's disease.*
- benzodiazepines in management of, 375–383
- neuroleptic drugs in management of, 355–356
- combined lesions causing, 244
- degenerative, primary, 239–240, 245
- depression in, prevalence of, 327–329
- depression-associated, 244–245, 329–330
- differential diagnosis of, neuropathologic findings and, 238–239
- established diagnostic criteria for, need for, 237–238
- multi-infarct, 241–244
- reversible, depression with, 329–330
- senile. *See Alzheimer's disease; Senile dementia.*
- subcortical, and Parkinson's disease, 240–241

Dementia Behavior Disturbance Scale, 322

Dementia Mood Assessment Scale, 321

Dependent personality disorder, comorbidity of MPD and, 562–563

Depersonalization, MPD and, 584

Depression, in Alzheimer's disease, 327–336

- assessments of, 320–321
- biologic findings in, 332–334
- clinical findings and family history of, 331–332
- clinical presentation and course of, 330–331
- differential diagnosis of, 334–335
- prevalence of, 327–329
- treatment of, 335–336
- dementia associated with, 244–245
- prevalence of, 327–329
- reversible, 329–330

ECT resistance and, treatment in, 917–920

family history of, and Alzheimer's disease, 331–332

Detachment, MPD and, 592–593

Development, atypical, 55–56

delayed, 55–56

identity and death instinct and, in MPD, 683–686

normal, 8–10, 21–23

sign stage of, in cognitive-developmental systems theory, 142–147

Developmental disorders, effects on family of, 183–195, 199–213

- systems perspective and, 200
- language impairment and, 99–104
- Asperger's syndrome versus, 85
- outcome and, 106–107
- pervasive. *See Pervasive developmental disorders.*

Developmental level, intraindividual differences in, 59–60

measures of, 58–60

DSM-IV and, 62–65

Deviance, social, in autism, 19–30

Diagnostic measures, results of, interpretation of, 75–76

Diazoxide, ECT and, 874–875

Differential learning, memory and, in MPD patients, 494–495

Diminished capacity, MPD and, 747

Direct observation, in diagnostic information collection, autism and, 74–75

Disabled child, family and, 199–213

- parental reactions to, 185–192

Dissociation. *See also Dissociative disorders; Multiple personality disorder (MPD).*

- contribution of, to other psychiatric disorders, 498
- epidemiology of, 490–491, 503–515
- history of, in child, 636
- "micro," MPD and, 579–580
- normative, 521–523
- as part of trauma response, 547–550
- psychophysiology of, 491–494
- recent research into, 490–498
- standardized measures of, 506–507

Dissociative disorders. *See also Dissociation; Multiple personality disorder (MPD).*

- assessment of, symptom cluster method for, 572–602
- childhood trauma and, 505–506
- in children and adolescents, 519–529. *See also Children, dissociative disorders in.*
- chronic complex, office mental status examination for, 567–602
- worldwide prevalence of, 511
- developmental antecedents of, 495–496
- inpatient diagnosis of, in children, 632–640
- prevalence of, 505
- in clinical populations, 507
- in general population, 508–515
- worldwide, 511
- psychological testing correlates of, 496–497

Dissociative disorders (*Continued*)
 specialized programs for, in hospitals, 715-717

Dissociative symptoms, complex, clinical mental status examination for, 568-571

Dopamine agonists, 115-117

Down's syndrome, Alzheimer's disease and, 259

Drugs. *See also* specific drug or type of drug.
 and cognitive impairment, 300-302
 effect on seizure threshold, in ECT, 816-819
 frontal lobe, 115-117
 interactions, ECT and, 895-896
 in MPD treatment, 721-738
 comorbidity and, 729-737
 in hospital, 714
 problems not solvable with, 727-729
 state-dependent effects in, 723-724
 total treatment context and, 724-727
 in pervasive developmental disorders, 165-179
 clinical guidelines for, 176-178
 fenfluramine, 172-173
 lithium carbonate, 174
 magnesium, 174-175
 methylphenidate, 171-172
 naltrexone, 173-174
 neuroleptic drugs, 166-171
 pyridoxine, 174-175
 seizures due to, 176
 selection for treatment, 175-176
 resistance to, ECT response and, 906-911, 920
 relapse following ECT and, 911-917, 920-921
 temporal lobe, 117-118

DSM-III-R, autistic disorder and, 61-62

Axis II disorders in, comorbidity of MPD and, 547-565

MPD criteria in, heterogeneity of individuals meeting, 510-511

DSM-IV, autistic disorder and, 53-67
 developmental measures and, 62-65

DuP 996, for cognitive impairment in Alzheimer's disease, 467

Dyskinesia, tardive, neuroleptic drugs causing, 167-171

Dyslexia. *See also* Language disorders.
 familiality of, 105

Dysphoria, maternal, parental stress and, effects on marital subsystem of, 206-210

ECT. *See* *Electroconvulsive therapy*.

Ectopy, agents reducing, in ECT, 875

Educational support, in nursing care, in electroconvulsive therapy, 971-972

EEG. *See* *Electroencephalography*.

Ego functioning, improvement of, child dissociative disorders and, 644-646

ElCoT, Inc., ECT devices, 1002-1004

Elective mutism, language impairment and, 100-101

Electroconvulsive therapy (ECT), 793-1020
 bilateral, efficacy of, 826, 827
 for mania, 892-893
 options for patients unresponsive to, 920
 cardiovascular effects of, 872-873
 risk management, 873-877
 cerebral effects of, 877-878
 risk management, 878-881
 clinical response to, speed of, 827-829
 devices for, battery operation, 1002
 displays and, 993, 999, 1001, 1003-1004
 ElCoT, Inc., 1002-1004
 glissando feature, 1002
 manufacturers of, 1005
 MECTA Corporation, 992-998
 Medcraft Corporation, 1000-1002
 patient monitoring and, 991-992, 993, 998, 999, 1001-1002, 1004
 printouts and, 993, 999, 1001, 1004
 programmable treatment options and, 1004
 selection of, 989-1005
 self-testing mechanisms and, 993, 999, 1001, 1003
 Somatics, Inc., 998-1000
 starter kit and, 998, 1000, 1002, 1004
 static impedance and, 993, 999, 1003
 stimulus energy and, 990-991, 992-993, 996-997, 998, 1000-1001, 1003
 wave form and, 990
 dosing in, absolute versus relative, 827
 drug interactions with, 895-896
 efficacy of, seizure duration and, 834-836
 stimulus intensity and, 822-829
 electrode placement in, seizure threshold and, 810-813
 inadequate seizures in, management of, 859-863
 informed consent and, 973, 1009-1010
 sample form for, 1017-1020
 legal and ethical issues in, 1007-1020
 low-dose, titrated, 823-826
 maintenance, 947-958
 in mania, 894-895
 nursing care in, 979-980
 for mania, 887-899
 in medically compromised patient, 871-881
 missed seizures in, detection of, 857-858

management of, 858–859
 monitoring and management in, 845–866
 equipment and, 991–992, 999–1000,
 1001–1002, 1004
 mania and, 896
 neuroendocrine testing in, 961–967
 nursing care in, 971–988
 optimal use of, 935–945
 in Parkinson's disease treatment, 925–931
 prolonged seizures in, defined, 863–864
 detection of, 864
 incidence of, 864
 management of, 864–865
 toxicity of, 864
 prophylactic. *See also Electroconvulsive therapy, maintenance.*
 in mania, 894–895
 regulatory issues, 897–898
 history of, 1008–1009
 relapse following medication resistance
 and, 911–917, 920–921
 resistance to, depression and, 917–920
 restimulation in, alternatives to, 860–861
 revival in United States of, antipsychiatry
 movement and, 793–800
 seizure duration in, 829–836
 efficacy and, 834–836
 factors related to, 829–834, 857
 seizure monitoring in, 845–857
 EEG in, 847–857
 motor response in, 845–847
 seizure threshold in, age and, 813–815
 anesthetic agents and, 815–816
 diagnostic categories and, 816
 dosing effects and, 808–810
 ECT devices and, 805
 electrode placement and, 810–813
 factors predicting or influencing, 810–
 822, 857
 gender and, 810
 psychotropic medications and, 816–819
 range in, 805–807
 stimulus intensity and, 804–822
 in special populations, 896–897
 stimulus intensity in, cognitive deficits
 and, 807–808
 efficacy and, 822–829
 seizure threshold, seizure duration and,
 803–838
 substitute consent and, 1010–1012
 treatment schedule for, 935–945
 current clinical practice, 936–937
 direct comparisons of, 941–944
 evidence from real versus simulated
 studies, 938–941
 implications of, 937–938
 in treatment-resistant patient, 905–921
 history of, 905–906
 medication resistance and response,
 906–911, 920
 relapse, 911–917, 920–921
 unilateral, efficacy of, 826, 827
 for mania, 892–893
 Electroencephalography (EEG), in clinical
 practice monitoring, evolution of, 847–
 848
 in ECT, 847–857
 ictal, interpretation of, 851–857
 scalp distribution of, 851
 time course of, 849–851
 recording method in, 848
 recording sites in, 848–849
 Electromyography (EMG), in
 electroconvulsive therapy, 847
 Embodied alternative identities, 769–785
 Emotional disorders, language impairment
 and, 100
 Emotional support, in nursing care, in
 electroconvulsive therapy, 971–972
 Engagement phase of sign stage of
 development, 144–145
 Extrathrallment, MPD and, 581
 Environment, child dissociative disorders
 and, inpatient treatment of, 640–643
 coping with, developmental dysfunctions
 and, 153–155
 Epochal multiple personality disorder, 622
 Ethical issues, in electroconvulsive therapy,
 1007–1020
 Experience, organization of, MPD and,
 538–539, 540–542
 Extrapiramidal effects of neuroleptic drugs,
 167–171

Familiality, of autism, 126–131
 of language impairment and related disorders, 105–106
 Family. *See also Parents.*
 handicapped child and, 199–213
 staff and, 160–161
 Family counseling, in Alzheimer's disease,
 385–390
 strategies for, 387–390
 Family education, Alzheimer's disease and,
 behavioral problems in, 347–348
 Family history studies. *See also Genetics.*
 in Alzheimer's disease, cumulative risk
 and, 269–275
 depression and, 331–332
 Family stress, models of, 184–185
 Family therapy, Alzheimer's disease and,
 390
 Fantasy play, 523–524
 Fantasy proneness, in adults, 524
 Fenfluramine, in pervasive developmental disorders, 172–173
 Financial impact, Alzheimer's disease and,
 caregiver and, 387

Flashbacks, MPD and, 589–590
 Forensic issues. *See also Legal issues.*
 multiple personality and, 741–755
 diagnostic evaluation of, 747–750, 762–765
 diminished capacity, 747
 evidentiary issues, 750–753
 iatrogenesis and malingering, 757–766
 insanity and competency to stand trial, 742–746
 malingering, 753–755, 757–766
 mitigation, 747
 Fractionated abreaction, MPD treatment and, 672–673
Fragile X, autism and, 131–133
Frontal lobe drugs, 115–117
Fugues, MPD and, 574–575
Functional Assessment Stairg., 320

Galatin, in Alzheimer's disease, 431–432
Genetic disorders, autism and, mechanisms of association of, 135
Genetic factors in autism, 125–137
Genetic transmission, models of, 126–131
Genetics. *See also Family history studies.*
 of Alzheimer's disease, 258–259, 267–284.
 See also Alzheimer's disease, clinical genetic studies of.
Geriatric Depression Scale, 321
Geropsychiatric patients, benzodiazepines in, 376–379
Global Deterioration Scale, 316
Global staging scales, Alzheimer's disease and, 315–318
Glucose metabolism, regional, Alzheimer's disease and, 449–450
Glutamatergic manipulations, for cognitive impairment in Alzheimer's disease, 470–471
Growth hormone, electroconvulsive therapy and, 965–966
Guardianship, Alzheimer's disease and, 391–392

Habits, fluctuations in, MPD and, 576–577
Hallucinations, MPD and, 582–583, 596–598
Haloperidol, 166–167
Handicapped child. *See Disabled child.*
Heart rate, ECT effects on, 872
 agents reducing heart rate and, 875
Hematoma, subdural, ECT and, 880
Hirano bodies, in Alzheimer's disease, 409
Histrionic personality disorder, comorbidity of MPD and, 553–554
Home. *See Family.*

Homicide defendants, forensic evaluation of.
 See also Forensic issues.
 iatrogenesis and malingering of MPD in, 757–766
Hydiazine, for cognitive impairment in Alzheimer's disease, 470
Hydralazine, ECT and, 875
Hyperactivity, language impairment and, 99–100
Hyperarousal symptoms, MPD and, 591–592
Hyperventilation, ECT and, 861
Hypnosis, legal evidence and, MPD and, 751–752
Hypothalamic pituitary adrenal axis,
 electroconvulsive therapy and, 962–964
Hypothalamic pituitary thyroid axis,
 electroconvulsive therapy and, 964–965

Identity(ies), alternative. *See also Alter personalities.*
 embodied, 769–785
development and death instinct and, in MPD, 683–686
 identifying, body and, 773–774
 mistaken, MPD and, 578–579
Imagery, intrusive, MPD and, 589–590
Imaginary companionship, 523–524
ostensible, MPD and, 623
Individual therapy, for caregiver, Alzheimer's disease and, 390
Informed consent, Alzheimer's disease and, 392–393
 research in, 393–394
 for ECT, 973, 1009–1010
 sample form for, 1017–1020
Inpatient treatment, of multiple personality disorder, 695–717
 in children, 631–647
 discharge criteria in, 704
 impact of hospital on patient, 706–707
 impact of patient on hospital, 704–706, 707–710
 indications for, 698–701
 lengths and goals of, 701–704
 management concerns with, 711
 outpatient psychotherapist and, 710–711
 patient participation and, 712
 special tracks in general programs for, 714–715
 specialized programs for, 715–717
 treatment issues arising in, 712–714
Insanity defense, MPD and, 742–746
Instrumental Activities of Daily Living Scale, 320
Integration, in MPD therapy, 670–674, 681–683, 689

Integrative spheres, in correction of developmental dysfunctions, 151

Intention, development of, during sign stage of development, 145-147

Interactive studies, autism and, 27

Interdisciplinary collaboration, nurse in, electroconvulsive therapy and, 980-981

Interference phenomena, multiple personality disorder and, 594-596

Intimacy, marital, parenting stress and psychological health and, 209-210

Intracranial pressure, brain tumor and, ECT and, 879

Intrusive imagery, MPD and, 589-590

IQ, and speech and language disorders, 97-98

Isomorphic multiple personality disorder, 622

Katz Activities of Daily Living Scale, 319

Ketamine, ECT and, 863

Knowledge, fluctuations in, MPD and, 576-577

Labetalol, ECT and, 876

Language, Alzheimer's disease and, scopolamine and, 298-299

Language disorders. *See also Communication.*

- autism and, 11, 23-25, 102-104
- correlates of, 97-99
- developmental disorders and, 99-104
 - Asperger's syndrome versus, 85
 - outcome and, 106-107
- elective mutism and, 100-101
- emotional disorders and, 100
- epidemiology of, 96-97
- familiarity of, 105-106
- hyperactivity and, 99-100
- learning disabilities and, 101-102

Learning, differential, in MPD patients, 494-495

Legal issues. *See also Forensic issues.*

- in Alzheimer's disease, 391-394
- in electroconvulsive therapy, 1007-1020
 - future directions of, 1014-1015
 - history of regulation, 1008-1009
 - informed consent, 1009-1010
 - sample form for, 1017-1020
 - malpractice, 1012-1013
 - right to effective treatment, 1013-1014
 - substitute consent, 1010-1012
- Leisure activities, of caregiver, Alzheimer's disease and, 387
- Lesions, combined, dementia due to, 244
- Lidocaine, ECT and, 875-876

Life history, fragmentary recall of, MPD and, 577-578

Linguistic dysfunction. *See also Language disorders.*

- continuum of, 95-107
- Linguistic usage, MPD and, 598
- Linkage studies, of Alzheimer's disease, 276-282
- Lithium carbonate, in pervasive developmental disorders, 174
- Living will, Alzheimer's disease and, 392
- Logic, trance, MPD and, 584-585

Magnesium, in pervasive developmental disorders, 174-175

Magnetic resonance imaging, in Alzheimer's disease, 446-449

Malingering, MPD and, 753-755, 757-766

Malpractice, electroconvulsive therapy and, 1012-1013

Mania, electroconvulsive therapy for, 887-889

- case vignettes of, 890-892
- double-blind trials of, 890
- historical background of, 887-890
- maintenance and prophylactic, 894-895
- mechanism of action of, 898-899
- number and frequency of treatments in, 893-894
- regulatory issues, 897-898
- side effects and complications of, 895-897
- technique of, 892-894

Marital relationship, effects of parental stress and maternal dysphoria on, developmentally handicapped child and, 206-210

Marital status, parental, and speech and language disorders, 99

Maternal dysphoria, parental stress and, effects on marital subsystem of, 206-210

Mattis Dementia Rating scale, 312

MECTA Corporation devices, for ECT, 992-998

Medcraft Corporation, ECT devices, 1000-1002

Medical illness, electroconvulsive therapy in, 871-881

Medication. *See Drugs; specific drug or type of drug.*

Mediumistic multiple personality disorder, 623

Memory. *See also Amnesia symptoms.*

- Alzheimer's disease and, scopolamine and, 297-298
- differential learning and, in MPD patients, 494-495

Memory Assessment Clinics Test Battery, 314

Mental health, of caregiver, Alzheimer's disease and, 387

Mental retardation, Asperger's syndrome versus, 85

Mental states, understanding of, autism and, 35-36

Mental status examination, office, for complex chronic dissociative symptoms and MPD, 567-602

Methylphenidate, in pervasive developmental disorders, 171-172

"Micro" dissociations, MPD and, 579-580

Mind, theory of in autism, 33-48

in normal children, 36-37

Mind deficit, theory of, social cognition and social behavior and, 34-35

Mini-Mental State Examination, 311-312

Minispheres, in correction of developmental dysfunctions, 150-151

Minority populations, and caregiving, in Alzheimer's disease, 390

Mistaken identity, chronic experiences of, MPD and, 578-579

Modular multiple personality disorder, 625-626

Monoaminergic drugs, for cognitive impairment in Alzheimer's disease, 467-468

Monoamines, in Alzheimer's disease, 423-424

Mood-stabilizing agents, in MPD, 734

Morbidity, ontogeny plus, 54-55

Multi-infarct dementia, 241-244

Multiple personality disorder (MPD), 489-791. *See also Dissociation; Dissociative disorders.*

- ad hoc, 625
- affective symptoms in, 601-602, 730-731
- amnesia symptoms in, 572-580
- anxiety in, 590-591, 732-736
- appearance of patient with, 570
- atypical, 623
- autohypnotic symptoms in, 580-586
- behaviors in, 570-571
- children with. *See also Children, dissociative disorders in.*
- inpatient treatment of, 631-647
- classic, 621
- clinical case management of, 650
- psychotherapy synthesis with, 650-651
- clinical phenomenology of, 497-498
- clinical presentations of, 605-627
- coconscious, 622
- comorbidity in, DSM-III-R Axis II disorders and, 547-565
- hospitalized patient and, 717
- psychopharmacology and, 729-737
- covert, 623-625

crisis management in, 657-659

crisis prevention in, 661-674

developmental antecedents of, 495-496

developmental substrates of, 520-526

diagnosis of, concerns involving, 608-609

- in forensic setting, 747-750, 762-765
- history of, 606-608

differential learning and memory in, 494-495

DSM-III-R criteria for, heterogeneity of individuals meeting, 510-511

epidemiology of, 490-491, 503-515

epochal, 622

extremely complex, 622

forensic issues in, 741-755

general coping style in, 537-538

hospital treatment of, 695-717

iatrogenesis model of, 511

identity, development, and death instinct in, 683-686

inherent instability and vulnerability in, 697-698

inner structure of, relationship to manifest appearance, 609-616

isomorphic, 622

longitudinal presentation of, 616-620

modular, 625-626

nature of, 609-610

office mental status examination for, 567-602

organization of experience in, 538-539

- traumatic, 540-542

orphan symptom, 625

ostensible imaginary companionship, 623

panic in, 590-591, 732-736

passive-influence dominated, 594-596

624

phenocopy, 624-625

polyfragmented, 622

possessioniform, 622-623

posttraumatic phenomena and, 539-540, 621-622

posttraumatic stress symptoms in, 586-593

psychopharmacologic treatment of, 732-736

private, 623

process symptoms in, 593-600

pseudo-false positive, 626

pseudoseizures in, 731-732

psychoanalytic perspective of, 677-689

psychological organization of, 533-545

psychological testing correlates of, 496-497

psychophysiology of, 491-494

psychotherapy and case management for, 649-659

psychotic-like symptoms in, 729-730

puppeteering, 624

quasi-roleplaying, 626

recent research on, 489–500
 reincarnation/mediumistic, 623
 Schneiderian symptoms and, 514
 secret, 623
 self-destructiveness in, 656–657, 737
 sequential, 622
 sleep problems in, 590, 736–737
 somatoform symptoms in, 600–601, 625, 731–732
 switch-dominated, 625
 transition phenomena in, 680–681
 treatment of, 498
 case examples of, 653–654
 cognitive model in, 662–674
 creative options in, 654–655
 dilution phase in, 671–674
 framework for, 656–657
 hospital, 695–717
 integration in, 670–674, 681–683, 689
 psychoanalytic, 677–689
 psychopharmacologic, 721–738
 psychotherapy and case management in, 649–659
 stabilization of, 661–674
 stages in, 699–701
 suppression phase in, 670–671
 working-through phase in, 686–689
 variant forms of, 621–623

Multispheres, in correction of developmental dysfunctions, 151–152

Mutism, elective, language impairment and, 100–101

Myocardial infarction, ECT and, 877

Naltrexone, in pervasive developmental disorders, 173–174

Narcissistic personality disorder,
 comorbidity of MPD and, 555–556

Negative hallucinations, MPD and, 582–583

Neuroanatomy, functional, of psychiatric treatments, 113–122

Neurobiopsychosocial model, 113

Neurochemistry, Alzheimer's disease and, 290–292

Neuroendocrine testing, in electroconvulsive therapy, 961–967
 growth hormone, 966
 hypothalamic pituitary adrenal axis, 962–964
 hypothalamic pituitary thyroid axis, 964–965
 neurophysins, 966–967
 prolactin, 965–966

Neurofibrillary tangles, in Alzheimer's disease, 406–409

Neuroimaging, in Alzheimer's disease, 443–455

Neuroleptic drugs. *See also Drugs; specific drug.*
 adverse effects of, 167–171
 for behavioral symptoms of Alzheimer's disease, 353–371
 efficacy of, 358–369
 toxicity of, 356–357, 368–371
 in pervasive developmental disorders, 166–171

Neurons, granulovacuolar degeneration of, in Alzheimer's disease, 409

Neuropathology, cholinergic system and, Alzheimer's disease and, 291–292
 and differential diagnosis of dementia, 238–239
 and learned adaptations, 56–57

Neuropeptide Y, in Alzheimer's disease, 426–427

Neuropeptides, in Alzheimer's disease, 424–432
 drugs affecting, for cognitive impairment in Alzheimer's disease, 468–469

Neurophysins, electroconvulsive therapy and, 966–967

Neuropsychologic tests, in Alzheimer's disease assessment, 313–315

Neurotensin, in Alzheimer's disease, 431

Neurotransmitter systems, and Alzheimer's disease, 288–300, 409–410, 422–424
 amino acid neurotransmitters, 432–433
 cholinergic system, 289–292
 pharmacologic approaches and, 292–300

Neurotrophic factors, and cognitive impairment in Alzheimer's disease, 471

New York University Test Battery, 314

Nifedipine, ECT and, 875

Nightmares, MPD and, 590

Nitrates, ECT and, 874

Nootropics, for cognitive impairment in Alzheimer's disease, 469–470

Normal children, development of theory of mind in, 36–37

Normal development, 21–23
 theory of, 8–10

Normative dissociation, 521–523

Numbing, MPD and, 592–593

Nursing care, in electroconvulsive therapy, 971–988
 areas for future research, 982–983
 educational and emotional support, 971–972
 informed consent and, 973
 interdisciplinary collaboration and, 980–981
 maintenance, 979–980
 posttreatment, 976–979
 pretreatment, 973–975
 during procedure, 975–976
 staff education and development for, 981–982

Nursing care (*Continued*)
standards of care, 985-988

Observation, in diagnostic information collection, autism and, 74-75

Obsessive-compulsive disorder, Asperger's syndrome versus, 85-86

Ontogeny, "atypical," 54-55

Orienting phase of sign stage of development, 143-144

Orphan symptom multiple personality disorder, 625

Ostensible imaginary companionship
multiple personality disorder, 623

Out-of-body experiences, MPD and, 584

Overtness, aspects of, in MPD, 612-616

Oxytocin, in Alzheimer's disease, 429, 430

Pacemakers, ECT and, 876

Paired helical filaments, in Alzheimer's disease, 406-409

Panic, MPD and, 590-591, 732-736

Paranoid personality disorder, comorbidity of MPD and, 550-551

Parents. *See also Family.*
age of, and Alzheimer's disease risk, 259
effects of developmental disorders on, 183-195, 200-206
interviews with, in diagnostic information collection, autism and, 73-74
marital status of, and speech and language disorders, 99
psychiatric illness in, and speech and language disorders, 99
stress in, developmentally handicapped child and, 200-204, 205
effects on marital subsystem of, 206-210
sources of, 204, 206

Parkinson's disease, Alzheimer's disease and, 259
subcortical dementia and, 240-241
treatment of ECT in, 925-931
neurobiologic basis of, 930
recommendations for, 930-931

Passive-aggressive personality disorder, comorbidity of MPD and, 563-564

Passive-influence symptoms, multiple personality disorder and, 594-596, 624

Passivity, in Alzheimer's disease, 345

Pedigree studies, of Alzheimer's disease, 276

Peptides. *See Neuropeptides.*

Personality disorders, MPD and, 550-564

Personality mapping, in MPD, 670-671

Personality system, in MPD, 611-612. *See also Alter personalities; Multiple personality disorder (MPD).*

Pervasive developmental disorders, 1-222

Asperger's syndrome, 81-91, 129

autism. *See Autism.*

cognitive-developmental systems theory in, 141-161

effects on family of, 183-195, 199-213

and functional neuroanatomy of psychiatric treatments, 113-122

linguistic dysfunction and, 95-107

use of medication in, 165-179. *See also Drugs.*

Pharmacologic models of Alzheimer's disease, 287-303

animal studies, 293-295

human studies, 295-299

Phenocopy multiple personality disorder, 624-625

Phenotype definition, and genetic transmission of autism, 128-130

Phobias, in MPD, 732-736

Physical Self-Maintenance Scale, 319-320

Physical wellbeing, of caregiver, Alzheimer's disease and, 386-387

Physiology. *See also Body.*
of multiple personality disorder, 491-494

Play, fantasy, 523-524

Polyfragmented multiple personality disorder, 622

Positron emission tomography, in Alzheimer's disease, 449-452

Possessioniform multiple personality disorder, 622-623

Possessions, unexplained, MPD and, 575

Possesstraumatic stress symptoms. *See also Trauma.*
in MPD, 539-540, 586-593, 621-622
psychopharmacologic treatment of, 732-736

Pregnancy, complications of, and speech and language disorders, 98-99

Primary degenerative dementia, 239-240
biologic markers of, need for, 245

Private multiple personality disorder, 623

Process symptoms, in mental status examination for assessment of MPD and dissociative disorders, 580-586

Prolactin, electroconvulsive therapy and, 965-966

Pseudo-false positive multiple personality disorder, 626

Pseudohallucinations, in MPD, 596-598

Pseudoseizures, in MPD, 731-732

Psychiatric disorders, childhood trauma in, rates of, 512-514
contribution of dissociation to, 498
parental, and speech and language disorders, 99

prevalence of, 504–505
Psychiatric treatments, functional neuroanatomy of, 113–122
Psychoanalytic perspective of multiple personality disorder, 677–689
Psychogenic amnesia, MPD and, 572–580
Psychological health, parenting stress and, marital intimacy and, 209–210
Psychological testing, in MPD and dissociative disorders, 496–497
psychological organization of patients as revealed in, 533–545
Psychological trauma. *See also Posttraumatic stress symptoms; Trauma.*
MPD and, 586–589
Psychomotor speed ability, Alzheimer's disease and, scopolamine and, 299
Psychopathology, in children, developmental and medical models for, 54–58
Psychopharmacology. *See Drugs.*
Psychophysiology, of MPD and dissociation, 491–494
Psychosis, in Alzheimer's disease, 345–346
Psychotherapy, case management and, for MPD, 649–659
Psychotic-like symptoms, in MPD, 729–730
Puppeteering multiple personality disorder, 624
Pyridoxine, in pervasive developmental disorders, 174–175

Quasi-roleplaying multiple personality disorder, 626
Questionnaires, in diagnostic information collection, autism and, 74

Reactivity, MPD and, 590–591
Reality systems, 142
evaluation of, Umwelt Assessment in, 147–149
formation and dynamics of, during sign stage of development, 143–145
Referrals, Alzheimer's disease and, family and, 389
Reincarnation/mediumistic multiple personality disorder, 623
Relationships, inexplicable changes in, MPD and, 576
Representation, development of, developmental dysfunctions and, 156–160
Research, on multiple personality disorder, 489–500
strategies for, autism and, 3–5
Revivifications, MPD and, 589–590

Ritual embodiment, 780–785

Schizoid personality disorder, comorbidity of MPD and, 551–552
Schizotypal personality disorder, Asperger's syndrome versus, 86
comorbidity of MPD and, 552–553
Scopolamine, and Alzheimer's disease, 295–299, 300
animal studies, 294
Secret multiple personality disorder, 623
Sedative-hypnotics, in MPD, 735–736
Seizures, electrically induced. *See Electroconvulsive therapy (ECT).*
neuroleptic drugs causing, 176
Self-destructiveness, in MPD, 656–657, 737
Senile dementia. *See also Alzheimer's disease.*
mild, 232–233
very mild, 230–232
Sequential multiple personality disorder, 622
Services referral, Alzheimer's disease and, family and, 389
Sex differences, and autism, 127, 128
and seizure threshold, in ECT, 810
Siblings, of developmentally handicapped child, 210–213
Sign stage of development, in cognitive-developmental systems theory, 142–147
development of intention during, 145–147
formation and dynamics of reality systems during, 143–145
Single photon emission computed tomography, in Alzheimer's disease, 452–454
Skills, fluctuations in, MPD and, 576–577
SKT Test battery, 314
Sleep, disturbance of, in Alzheimer's disease, 346
in MPD, 590, 736–737
Social activities, of caregiver, Alzheimer's disease and, 387
Social behavior, social cognition and, theory of mind deficit and, 34–35
Social contact, development of, developmental dysfunctions and, 155–156
Social deviance, in autism, 11, 19–30
Social impairments, Wing's triad of, 61
Socioeconomic status, and speech and language disorders, 97
Somatics, Inc., ECT devices, 998–1000
Somatoform symptoms, in MPD, 600–601, 625, 731–732
Somatostatin, in Alzheimer's disease, 424–427

Spectroscopy, magnetic resonance imaging, in Alzheimer's disease, 449

Speech disorders. *See also Language disorders.*
correlates of, 97-99

Spheres, in correction of developmental dysfunctions, 149-152

Staff, education and development, for nursing care in ECT, 981-982
family and, 160-161

MPD patient's effect on, 704-706
coping with, 707-710
pediatric, 646

Standards of care, nursing, for patient receiving ECT, 985-988

Stress, family, models of, 184-185
parenting, developmentally handicapped child and, 200-204, 205
effects on marital subsystem of, 206-210
sources of, 204, 206

posttraumatic. *See Posttraumatic stress symptoms.*
MPD and symptoms of, 586-593

Stroke, ECT and, 880-881

Subcortical dementia, and Parkinson's disease, 240-241

Subdural hematoma, ECT and, 880

Substance P, in Alzheimer's disease, 430-431

Substitute consent, for electroconvulsive therapy, 1010-1012

Support, in nursing care, in electroconvulsive therapy, 971-972

Support groups, Alzheimer's disease, 390

Surgery, cardiac, ECT and, 877

Surroundings, coping with, developmental dysfunctions and, 153-155

Switch-dominated multiple personality disorder, 625

Switching, in MPD, 598-600

Sympathoadrenal cardiovascular effects, prevention of, ECT and, 874-876

Symptom cluster method, for assessment of MPD and dissociative disorders, 572-602
affective symptoms in, 601-602
amnesia symptoms in, 572-580
autohypnotic symptoms in, 580-586
posttraumatic stress symptoms in, 586-593
process symptoms in, 593-600
somatoform symptoms in, 600-601

Synchrony of contact, autism and, 27

Systems perspective, on effects of developmental handicap, 200

Tardive dyskinesia, neuroleptic drugs causing, 167-171

Temporal lobe drugs, 117-118

Tetrahydrocannabinol (THC), and cholinergic function, 299

Theory of mind hypothesis. *See also Mind theory of.*
autism and, 33-34

Therapeutic alliance, child dissociative disorders and, 643-644

Thioridazine, 176
and cholinergic function, 299-300

Thought disorder, dissociative, 584-585

Thymatron, 998-1000

Thyroid disease, Alzheimer's disease and, 259, 261

Thyrotropin releasing hormone, in Alzheimer's disease, 431-432

Time loss, MPD and, 573

Time sense, in children, 525

Trance logic, MPD and, 584-585

Trances, spontaneous, MPD and, 580-581

Trauma. *See also Posttraumatic stress symptoms.*
cerebral, ECT and, 880-881
childhood, developmental substrates of multiple personality disorder and, 525-526
dissociative disorders and, 505-506
psychiatric disorders and, 512-514
psychological, MPD and, 586-589

Trauma response, dissociation as part of, 547-550

Traumatic experience, organization of, MPD and, 540-542

Traumatic reenactment, MPD and, 657-658

Treatment-resistant patient, electroconvulsive therapy in, 905-921

Tricyclic antidepressants. *See Antidepressants, tricyclic.*

Trifluoperazine, 167

Trimethaphan, ECT and, 874

Tuberous sclerosis, autism and, 133-135

Tumor, brain, ECT and, 878-880

Twin studies, of Alzheimer's disease, 268-269

Umwelt Assessment, 147-149

Vagal cardiovascular effects, prevention of, ECT and, 873-874

Vascular disease, dementia due to, Alzheimer's disease and, 411

Vasoactive intestinal peptide, in Alzheimer's disease, 431

Vasopressin, in Alzheimer's disease, 429-430

Videotaping, legal evidence and, MPD and, 750

Visuospatial ability, Alzheimer's disease and, scopolamine and, 299

Vitamin B₆, in pervasive developmental disorders, 174-175

Voluntary anesthesia/analgesia, MPD and, 583-584

Wandering behavior, in Alzheimer's disease, 344-345

White matter, Alzheimer's disease and, 446-447

Wing's triad of social impairments, 61

Withdrawal emergent syndrome, 169-170